The dialysis market is projected to grow at a CAGR of approximately 8% during the forecast period. This growth is driven by ...

Groupon, with over 22.5 million active users and generating more than $550 million in annual revenue, now features CBDL's top-tier wellness products, unlocking massive e-commerce potential and ...

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the completion of the acquisition of Biotheus ...

Coming In 2025, microFET2 New Features and Accessories to Be Introduced at The Conference. SALT LAKE CITY, UTAH / ACCESS Newswire / February 4, 2025 / Hoggan Scientific, LLC, a global leader in the ...

Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform, and 3PBIOVIAN, a leading contract development and manufacturing organization (CDMO), ...

ACI Group, a leading supplier of high-quality, sustainable natural ingredients, is expanding its product range through a strengthened partnership with Orcas Naturals. In a complex landscape where ...

With Northway Biotech's expertise in biologics manufacturing, Mallia aims to enter the multi-billion-dollar alopecia market by delivering a safe and effective topical sCD83 treatment designed to ...

Best For You is pleased to announce the release of three new films for young people and families, marking the launch of a weekly series created with backing from YouTube.   With research showing over ...

ProBioGen has launched its new, redesigned website to provide biotech and biopharma professionals with clear access to its expanded services and proprietary technologies. The platform delivers an ...

Alys Pharmaceuticals, Inc. (“Alys”), an immune-dermatology focused company, today announces that the U.S. Food and Drug Administration (FDA) and Health Canada have cleared the Investigational New Drug ...

The Organising Committee is delighted to announce the seventh edition of the EAACI-ESCD Skin Allergy Meeting (SAM), Europe’s leading event dedicated to skin allergies. This year, SAM 2025 will take ...

Akribion Therapeutics (“Akribion”), the early-stage biotech developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announces its exit from stealth and the ...